Get the Stockscreener App
0.6598
1.51%
0.0098
After Hours:
2.66
2.0002
+303.15%
Gt Biopharma Inc stock is traded at $0.6598, with a volume of 929.98K.
It is up +1.51% in the last 24 hours and down -9.01% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$0.65
Open:
$0.661
24h Volume:
929.98K
Relative Volume:
0.47
Market Cap:
$7.02M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.0953
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
+8.27%
1M Performance:
-9.01%
6M Performance:
-76.60%
1Y Performance:
-75.92%
1-Day Range:
$0.635
$0.6726
1-Week Range:
$0.61
$0.7124
52-Week Range:
$0.54
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.66 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.30 | 268.44M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.14 | 223.06M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.7287 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.74 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
GT Biopharma, Inc. Reports Continued Progress with Its Phase 1 Clinical Trial of GTB-3650 - marketscreener.com
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market - The Manila Times
What is GT Biopharma Inc (GTBP) Stock Return on Shareholders’ Capital? - setenews.com
GT Biopharma Inc Stock Analysis and ForecastDay Trading Setups & Free Lightning Fast Capital Gains - earlytimes.in
GT Biopharma (GTBP) Stock Analysis Report | Financials & Insights - Benzinga
Why GT Biopharma Inc. (OXIA) stock could rally stronglyJuly 2025 Recap & Daily Price Action Insights - Newser
GT Biopharma Inc OXIA Stock Analysis and ForecastMarket Sentiment Shifts & Affordable Portfolio Trading - earlytimes.in
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha
What technical charts say about GT Biopharma Inc. stockTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
What is the fair value estimate for GT Biopharma Inc. (OXIA) stock in 2025July 2025 Trade Ideas & Daily Risk Controlled Trade Plans - Newser
The growth track for GT Biopharma Inc (GTBP) has changed recently - Setenews
What Wall Street predicts for GT Biopharma Inc. stock priceTrade Entry Report & Fast Exit and Entry Strategy Plans - Newser
Is GT Biopharma Inc. (OXIA) stock a buy on weaknessWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
How supply chain issues affect GT Biopharma Inc. stockRate Hike & Consistent Income Trade Ideas - Newser
How reliable is GT Biopharma Inc. (OXIA) stock dividend growthWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What drives GT Biopharma Inc stock priceShort Interest Overview & Superior Trading Portfolio - earlytimes.in
GT Biopharma faces Nasdaq bid-price deficiency, eyes compliance options - Stock Titan
A History of Outperforming Analyst Forecasts and Beating the Odds: GT Biopharma Inc (GTBP) - Setenews
GT Biopharma shares advance as flagship GTB 3650 trial escalates to next dose level - MSN
GT Biopharma (GTBP) Price Target Decreased by 27.27% to 8.16 - MSN
How GT Biopharma Inc. (OXIA) stock responds to job market shiftsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Is GT Biopharma Inc. (OXIA) stock a fit for income portfoliosPortfolio Risk Summary & Risk Adjusted Swing Trade Ideas - newser.com
Will GT Biopharma Inc. (OXIA) stock extend growth storyWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com
Will GT Biopharma Inc. (OXIA) stock deliver compounding returns2025 Earnings Surprises & Safe Entry Momentum Tips - newser.com
Is GT Biopharma Inc. stock attractive for income investorsWatch List & Stepwise Entry and Exit Trade Signals - newser.com
Developing predictive dashboards with GT Biopharma Inc. dataChart Signals & Daily Entry Point Alerts - newser.com
Is GT Biopharma Inc. trending in predictive chart models2025 Price Targets & Weekly Stock Breakout Alerts - newser.com
Will GT Biopharma Inc. bounce back from current supportQuarterly Trade Review & Accurate Trade Setup Notifications - newser.com
Is GT Biopharma Inc. (OXIA) stock positioned for secular growth2025 Big Picture & Capital Efficiency Focused Ideas - newser.com
Tools to monitor GT Biopharma Inc. recovery probabilityMarket Risk Report & Real-Time Market Trend Scan - newser.com
GT Biopharma stock rises as Phase 1 trial advances to higher dose - Investing.com Nigeria
GT Biopharma stock rises as Phase 1 trial advances to higher dose By Investing.com - Investing.com South Africa
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):